ProCE Banner Activity

Staying on Target: Reducing CV Risk by Achieving LDL-C Targets With Statin and Nonstatin Therapies


Download these slides to learn the latest evidence on the comprehensive management of hyperlipidemia, including the importance of achieving LDL-C targets, addressing elevated Lp(a), optimally positioning all agents in the lipid armamentarium, and partnering with patients to reduce ASCVD risk.

Released: April 15, 2024

Expiration: April 14, 2025



Ty J. Gluckman

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Michael Miller

Michael Miller, MD, FACC, FAHA

Cardiologist & Professor of Medicine
Hospital of the University of Pennsylvania
Chief of Medicine
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation